Digital Health Innovation and Informatics

PV QA 2 - Poster Viewing Q&A 2

MO_17_2595 - App-based PRO monitoring in geriatric patients undergoing radiation therapy - an initial analysis of the prospective TeleGraPH trial.

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

App-based PRO monitoring in geriatric patients undergoing radiation therapy – an initial analysis of the prospective TeleGraPH trial.
F. A. Giordano1, V. Siefert2, G. Welzel3, M. Blessing3, C. Neumaier3, L. Jahnke1, J. Hesser4, and F. Wenz1; 1Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, 2Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany, 3Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany, 4Experimental Radiation Oncology, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany

Purpose/Objective(s): Recent randomized trials indicated that electronic assessment of PRO may significantly improve overall survival of patients with metastatic cancers. Although this is a major advancement in palliative cancer care, there were concerns that only young(er) patients with access to mobile devices may benefit from such digital cancer care. We therefore initiated TeleGraPH (Telemonitoring of Geriatric Cancer Patients Using Handheld Devices), a prospective trial assessing the compliance of elderly cancer patients to use handheld devices for symptom and QoL reporting during/after radiotherapy.

Materials/Methods: TeleGraPH is a prospective feasibility study on an App-based symptom and QoL follow-up (CareOnlineTM, humediQ GmbH, Grünwald) in geriatric cancer patients. Inclusion Criteria were age>60, KPS ≥ 70 and a histologically confirmed primary tumor. Primary outcome is compliance (defined as number of questionnaires answered per time frame, time frame: 0-3 months after enrollment), secondary outcome is HRQL (EORTC-QLQ30). Additional items were the subjective perception of the health status (SPHS) as well as the body weight. We here report data from an interim analysis on compliance and an (exploratory) comparative analysis between curative and palliative patients. The trial is registered with ClinicalTrials.gov, number NCT03196050.

Results: A total of 48 patients were included in this interim analysis. 18 patients (38%) were excluded due to personal or study- related issues after enrollment. The median follow-up was 3.5 months (0.4-13.9 months). The most frequent primary disease was prostate cancer (37%), followed by breast cancer (10%), small-cell-lung-cancer (10%) and glioblastoma (10%). The mean compliance after 15 days was 73% decreasing to 55% after 90 days. There were no significant differences with regard to compliance between the curative and palliative groups. However, the palliative group showed a decrease in weight and little to no improvements in SPHS whereas the weight was stable and the SPHS improved in the curative group.

Conclusion: This trial established important benchmarks for future digital care of geriatric cancer patients. Roughly 60% of all geriatric cancer patients participate in App-based follow-up during/after radiotherapy, ¾ of those respond within the first 2 weeks and ½ will use this follow-up technology for more than three months. Funded by the Federal Ministry of Economic Affairs of Germany, the H.W. & J. Hector Foundation and humediQ GmbH.

Author Disclosure: F.A. Giordano: None. V. Siefert: None. G. Welzel: None. M. Blessing: None. C. Neumaier: Independent Contractor; carl zeiss meditec. Honoraria; carl zeiss meditec. F. Wenz: Research Grant; Elekta AB, Carl Zeiss Meditec AG. Honoraria; Roche Pharma AG. Consultant; Celgene.

Frank Giordano, MD

Biography:
Positions and Appointments
2018- Vice Chair, Dept. of Radiation Oncology, University Medical Center Mannheim
2017 Attending Physician, Dept. of Radiation Oncology, University Medical Center Mannheim
2017- Associate Professor
2016- Board Certification, Radiation Oncology
2015- Head, Translational Radiation Oncology, University Medical Center Mannheim
2012-2016 Residency / Physician Scientist, Dept. of Radiation Oncology, University Medical Center Mannheim (with Frederik Wenz)
2010-2012 Physician Scientist, National Center for Tumor Diseases (NCT) Heidelberg (with Christof von Kalle)
2008-2009 Physician Scientist, German Cancer Research Center and Department of Hematology and Oncology, University of Heidelberg (with Anthony Ho)
2006 Sub-intern, Memorial Sloan Kettering Cancer Center (with Marcel van den Brink, Juliet Barker and Stephen Nimer)

Education
2009 USMLE Step 3 (New York, NY)
2008 MD thesis, German Cancer Research Center (magna cum laude)
2008 ECFMG Certificate
2008 USMLE Step 2 CS (Houston, TX)
2007 German Medical Licensure (MD), University of Heidelberg (GPA: 1.66 / Top 3%)
2006 USMLE Step 2 CK (New York, NY)
2005 USMLE Step 1 (Top 9% of graduates, Frankfurt)

Honors and Awards
2018 Else-Kröner Fresenius Excellence Fellowship
2017 Honorary Member, Spanish Society of Radiation Oncology (SEOR)
2015 ASTRO Translational Science Abstract Award
2013 DEGRO Anna-Hamann travel award
2010 Peter and Traudl Engelhorn Fellowship
2006 McKinsey EuroAcademy Athens (invited)
2005- Multiple travel awards (EU/Marie Curie Actions, ISCT)

Presentation(s):

Send Email for Frank Giordano


Assets

MO_17_2595 - App-based PRO monitoring in geriatric patients undergoing radiation therapy - an initial analysis of the prospective TeleGraPH trial.



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for App-based PRO monitoring in geriatric patients undergoing radiation therapy - an initial analysis of the prospective TeleGraPH trial.